| Glargine | diabetes type 2, in all type of patients | vs premixed insulin analogues | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | Coronary event | no data | | Cardiovascular death | no data | | Death from cancer | no data | | Fatal MI | no data | | Heart failure | no data | | Long term death | no data | | Fatal stroke | no data | | Non fatal stroke | no data | | Non fatal MI | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | cardiovascular events | no data | | cardiac event (fatal and non fatal ) | no data | | non cardiovascular death | no data | | macrovascular events | no data | | microvascular events | no data | | nephropathy | no data | | retinopathy | no data | | macrovascular or microvascular events | no data | | fatal HF | no data | | Peripheral vascular events | no data | | long term cardiovascular events | no data | | vision loss | no data | | severe hypoglycemia | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Levin, 2011 | | | |
|
